Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
17 results
D3.101 - Etoricoxib Associated Fixed Drug Eruption: A Case Series from a Tertiary Allergy and Clinical Immunology Centre, United Arab Emirates
D3.93 - Clinical Efficacy of Tezepelumab in a Patient with Severe Refractory Mixed Asthma: A Case Report from Kazakhstan
D3.95 - Hidden in everyday cosmetics: Facial allergic contact dermatitis to fragrances
D3.97 - Allergic contact dermatitis confirmed by repeated open application test in a 68‑year‑old patient
D3.98 - An extended study for the multiple detection of IgE-mediated allergic reactions using microarray technology
D3.104 - Molecular Co-Sensitization Mapping Using a 192-Line Multiplex IgE Platform
D3.105 - Analysis of post-vaccination immunity in children with dermatology diseases receiving biologic and immunosuppressive therapy
D3.107 - Comparison of Cupressaceae sensitization allergens in a large Spanish cohort
D3.103 - Comprehensive Allergen Characterization for Standardized Basophil Activation Testing
D1.437 - A Decade of Research on Janus Kinase Inhibitors in Atopic Dermatitis: A Global Bibliometric Analysis (2015–2024)
D1.438 - Dupilumab for Moderate-to-Severe Atopic Dermatitis in Children and Adolescents: Real-Life Assessment of Efficacy and Safety
D1.442 - Design and Preclinical Development of a Bispecific Antibody Targeting IL11 and TL1A
D1.443 - Preclinical Development of a Dual LIGHT/TL1A Bispecific Antibody
D1.447 - Comparison of Disease Duration, Remission, and Other Disease-Related Parameters with the Duration of Omalizumab Treatment in Patients with Chronic Spontaneous Urticaria
D1.448 - Long-Term Efficacy and Stability of Lebrikizumab in Treating Face/Head and Neck Involvement in Patients with Moderate-to-Severe Atopic Dermatitis
D1.449 - A Phase 2, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Briquilimab in Adults with Chronic Urticaria (Trial in Progress)
D1.439 - Urticaria Voices: Physician-reported perspectives of chronic urticaria care and its treatment in China (UV in China)
Download the app
The congress at your fingertips
Available on
Download